Premier Research, a global clinical research, product development, and consulting company, and BioCentriq, a contract development and manufacturing organization (CDMO), have entered a strategic partnership to advance the pre-investigational New Drug (IND) process and accelerate the clinical translation of novel cell therapy products.

By leveraging Premier Research’s expertise in cell therapy product development and regulatory expertise, with BioCentriq’s proficiency in developing, manufacturing, and testing cell therapies, the partnership aims to streamline product development from pre-IND through approval.

“Partnering with BioCentriq aligns with our commitment to expediting the development of transformative cell therapies,” said Kenneth Ndugga-Kabuye, vice president, cell, and gene therapy at Premier Research. “By merging our comprehensive product development expertise with BioCentriq’s specialized capabilities we will help sponsors simplify the development process from pre-IND through approval, ultimately accelerating the delivery of innovative therapies to patients in need.”

“This collaboration marks a significant step in fostering a more streamlined pathway for groundbreaking cell therapies,” said Alex Klarer, vice president, business strategy, and innovation at BioCentriq. “Combining Premier Research’s clinical insights with our CDMO expertise will empower us to expedite the translation of novel therapies from the lab to clinical reality, benefiting patients worldwide.”